New Immunogenicity Analysis Tool Emerges from Dartmouth-EpiVax-URI Collaboration “In Silico” Host Cell Protein for Protein Therapeutics

A Public-private partnership resulted in the development of a new web-based tool that will help manufacturers of protein-based therapeutics improve the safety of their manufacturing processes, avoiding problems that caused the FDA to suspend a clinical trial in 2012 for a Factor IX protein.